Advances in Clinical and Experimental Medicine
2018, vol. 27, nr 6, June, p. 765–772
Publication type: original article
Quality control of riboflavin-treated platelet concentrates using Mirasol® PRT system: Polish experience
1 Institute of Hematology and Transfusion Medicine, Warszawa, Poland
2 Regional Blood Transfusion Center, Warszawa, Poland
3 Terumo BCT Biotechnologies, Lakewood, USA
Background. The quality of platelet concentrates (PCs) is affected by preparation, storage, the type of container, and pathogen reduction technology (PRT). The Mirasol® Pathogen Reduction Technology (PRT) system (Terumo BCT Inc., Lakewood, USA), which uses riboflavin and ultraviolet (UV) light, has recently been proven effective against bacteria, viruses, parasites, and leukocytes.
Objectives. The aim of the study was to evaluate the effect of the Mirasol® PRT system, based on riboflavin and UV light exposure, on the most common in vitro platelet quality parameters of PCs prepared from whole blood-derived buffy coats.
Material and Methods. The study included 15 trials (n = 15). For each trial, 2 PCs were used: 1 for treatment with the Mirasol® PRT system (M) and 1 for a control (C). In the M group, PCs were illuminated. In the C group, saline solution was added. PCs from groups M and C were stored at 20–24°C, with agitation. Samples were collected on days 1, 3 and 5 to determine platelet concentration, total platelet count/unit, mean platelet volume (MPV), power of hydrogen (pH), glucose and beta-thromboglobulin concentration (BTG), hypotonic shock response (HSR), aggregation, CD42b and CD62P expression, pCO2, and pO2.
Results. No significant differences in HSR or CD42b expression were observed between groups M and C. All pH values were stable during the whole storage period (7.1–7.5). On storage day 1, CD62P expression in group C was significantly higher than in group M. In the Mirasol® group, significantly higher glucose consumption was noted on storage days 3 and 5. On day 5, a 2–3-fold increase in BTG was observed in both groups as compared to day 1; on day 5, BTG concentration was 32% higher in group M than in group C. On all storage days, pCO2 was comparable in groups M and C; lower pO2 values were reported for group M.
Conclusion. In vitro results demonstrated that pH, HSR, aggregation, CD42b antigen expression, and MPV and platelet count parameters were comparable in groups M and C.
pathogen, platelets, inactivation
- Lachert E, Kubis J, Dąbrowska A. Quality system in blood transfusion service. In: Łętowska M, ed. Medical Standards for Collection, Preparation and Distribution of Blood and Blood Components. 3rd ed. Warszawa: Institute of Hematology and Transfusion Medicine; 2014:41–105.
- Klein HG, Bryant BJ. Pathogen-reduction methods: Advantages and limits. Vox Sang. 2009;4:154–160.
- Hayes EB, Komar N, Nasci RS, Montgomery SP, O’Leary DR, Campbell GL. Epidemiology and transmission dynamics of West Nile virus disease. Emerg Infect Dis. 2005;11:1167–1173.
- Biggerstaff BJ, Petersen LR. Estimated risk of transmission of the West Nile virus through blood transfusion in the US, 2002. Transfusion. 2003;43:1007–1017.
- Canellini G, Waldvogel S, Anderegg K, Tissot JD. Bacterial contamination of platelet concentrates: Perspectives for the future. Labmedicine. 2010;41(5):301–305.
- Cardo LJ, Rentas FJ, Ketchum L, et al. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light. Vox Sang. 2006;90:85–91.
- Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion. 2004;44:877–885.
- Fast LD, DiLeone G, Li J, Goodrich R. Functional inactivation of white blood cells by Mirasol treatment. Transfusion. 2006;46:642–648.
- Fiebig E, Hirschkorn DF, Maino VC, Grass JA, Lin L, Busch MP. Assessment of donor T-cell function in cellular blood components by the CD69 induction assay: Effects of storage, γ radiation, and photochemical treatment. Transfusion. 2000;40:761–770.
- Ambruso DR, Thurman G, Marschner S, Goodrich RP. Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates. Transfusion. 2009;49:2631–2636.
- Cazenave JP, Follea G, Bardiaux L, et al. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion. 2010;50:2362–2375.
- Ness P, Braine H, King K, et al. Single-donor platelets reduce the risk of septic platelet transfusion reactions. Transfusion. 2001;41:857–861.
- Ali SF. Platelet activation in stored platelet concentrates: Comparison of two methods preparation. J Hematol. 2012;1:15–19.
- Slichter SJ, Corson J, Jones MK, Christoffel T, Pellham E, Bolgiano D. Platelet concentrates prepared after a 20- to 24-hour hold of the whole blood at 22°C. Transfusion. 2012;52:2043–2048.
- Tudisco C, Jett BW, Byrne K, Oblitas J, Leitman SF, Stroncek DF. The value of pH as a quality control indicator for apheresis platelets. Transfusion. 2005;45:773–778.
- Picker SM. In vitro assessment of platelet function. Transfus Apher Sci. 2011;44:305–319.
- Moroff G, George VM, Siegl AM, Luban NLC. The influence of irradiation on stored platelets. Transfusion. 1986;26:453–456.
- Murphy S, Rebulla P, Bertolini F, et al. In vitro assessment of the quality of stored platelet concentrates. Transfus Med Rev. 1994;8:29–36.
- Rinder HM, Smith BR. In vitro evaluation of stored platelets: Is there hope for predicting post-transfusion platelet survival and function? Transfusion. 2003:43:2–6.
- Li J, Lockerbie O, de Korte D, Rice J, McLean R, Goodrich RP. Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology. Transfusion. 2005;45:920–926.
- Goodrich RP, Li J, Pieters H, Crookes R, Roodt J, Heyns A. Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects. Vox Sang. 2006;90:279–285.
- Valeri CR, Feingold H, Marchionni LD. The relation between response to hypotonic stress and the 51Cr recovery in vivo of preserved platelets. Transfusion. 1974;14:331–337.
- Handin RI, Fortier NL, Valeri CR. Platelet response to hypotonic stress after storage at 4°C or 22°C. Transfusion. 1970;10:305–309.
- Kraemer L, Raczat T, Weiss DR, Strobel J, Eckstein R, Ringwald J. Correlation of the hypotonic shock response and extent of shape change with the new ThromboLUX™. Vox Sang. 2015;9:194–196.
- Rijkers M, van der Meer PF, Bontekoe IJ, et al. Evaluation of the role of the GPIb-IX-V receptor complex in development of the platelet storage lesion. Vox Sang. 2016. doi:10.1111/vox.12416
- Shrivastava M. The platelet storage lesion. Transfus Apher Sci. 2009;41:105–113.
- Macher S, Sipurzynski-Budrass S, Rosskopf K, et al. Function and activation state of platelets in vitro depend on apheresis modality. Vox Sang. 2010;99:332–340.
- George JN. Changes in platelet membrane glycoproteins during blood bank storage. Blood Cells. 1992;18:501–511.
- Fijnheer R, Modderman PW, Veldman H, et al. Detection of platelet activation with monoclonal antibodies and flow cytometry: Changes during platelet storage. Transfusion. 1990;30:20–25.
- Fijnheer R, Pietersz RN, de Korte D, et al. Platelet activation during preparation of platelet concentrates: A comparison of the plateletrich plasma and the buffy coat methods. Transfusion. 1990;30:634–638.